Publications

The Swiss Cancer Institute has a very high publication rate of over 95%. An article published in 2023 examined how often our studies were published, including 240 studies that completed patient recruitment between 1986 and 2021.

216 of 240 studies (90%) were published in peer-reviewed journals, 14 were published in other formats, giving an overall publication rate of 96%.

Studies that were completed earlier were less likely to be published. However, even for these studies, the publication rate was around 80%, which is significantly higher than stated in the literature.

Learn more

Hayoz S, Kasenda B, Schenker AL, et al. Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK). BMJ Open 2023;0:e068490. doi:10.1136/

In 2024, 38 articles relating to the Swiss Cancer Institute (formerly SAKK) appeared in various scientific journals. The number of articles is comparable to previous years. Under its former name "SAKK", the Swiss Cancer Institute was well represented with 18 posters and 23 presentations at the most important oncology congresses and local events.

A particular highlight was the oral presentation of the SAKK 41/13 aspirin study at the European Society for Medical Oncology (ESMO) congress in Barcelona. This randomized, placebo-controlled phase III trial investigated the use of adjuvant aspirin treatment in patients with PIK3CA-mutated colorectal cancer.

An overview table with the number of manuscripts and conference presentations compared to previous years can be found in the Annual Report.